PolyPeptide Group

Historical price data

PolyPeptide Group AG is a Swiss-based, publicly traded CDMO and a global leader in peptide API development and manufacturing. Its mission is to partner with pharmaceutical and biotech clients to secure regulatory approvals and successfully commercialize peptide-based drugs, contributing to therapies for millions of patients worldwide. The company's strategy leverages deep, decades-long technical expertise, a global network of GMP facilities, and a strong pipeline of custom projects to capitalize on the rapidly expanding peptide therapeutics market, especially in metabolic diseases like diabetes and obesity. Its integrated service model and operational excellence underpin its position as a preferred partner in a complex and high-growth niche.

An integrated peptide CDMO platform built on 70+ years of expertise, encompassing pre-GMP development, custom research-grade synthesis, clinical & commercial GMP manufacturing, radiolabeling, and full regulatory support, without reliance on a single proprietary technology.

Competes directly with specialized peptide CDMOs like Bachem and the peptide units of large, diversified CDMOs (e.g., Lonza, Catalent). Its competitive advantages are its pure-play focus, seven-decade heritage, proven track record with over 1,000 GMP peptides, and established position as a critical supplier in the high-growth GLP-1 market.